Moleculin announced it has entered into a collaboration with scientists in Poland to expand the understanding of Moleculin’s leading STAT3 inhibitor WP1066 and the Company’s newly discovered drug candidate, WP1732.
Moleculin announced it has entered into a collaboration with scientists in Poland to expand the understanding of Moleculin’s leading STAT3 inhibitor WP1066 and the Company’s newly discovered drug candidate, WP1732.